Description
Hexamethylene bisacetamide (HMBA) activates hexamethylene bisacetamide-inducible protein 1 (HEXIM1), inhibiting transcription elongation factor b (P-TEFb), a regulator of RNA polymerase II and mRNA synthesis. HMBA exhibits anticancer activity and is used to induce cellular differentiation and apoptosis in cancer cells. HMBA also inhibits activation of NF-κB, Akt, and ERK.
References
Lew QJ, Chia YL, Chu KL, et al. Identification of HEXIM1 as a positive regulator of p53. J Biol Chem. 2012 Oct 19;287(43):36443-54. PMID: 22948151.
Dey A, Wong E, Kua N, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67. PMID: 19029824.
Zhang Z, Liong EC, Lau TY, et al. Induction of apoptosis by hexamethylene bisacetamide is p53-dependent associated with telomerase activity but not with terminal differentiation. Int J Oncol. 2000 May;16(5):887-92. PMID: 10762623.